This limitation impedes rapid insights into various aspects of menin inhibitors, including side effects, efficacy across leukemia subtypes and fusion partners, variability in inhibitor efficacy, resistance mechanisms, and effective combinations pre and post HSCT (Fig. 4). The gene discussed is MEN1; the disease is leukemia.